ArriVent BioPharma, Inc. AVBP Proceeds from disposition of marketable securities and other investments

Proceeds from disposition of marketable securities and other investments at other companies

Johnson & JohnsonJNJ

$209M-4.1%

Bicara TherapeuticsBCAX

——

Jazz PharmaceuticalsJAZZ

——

Operating income-$46.1M+30.9%

Net income-$43.3M+32.7%

EPS (diluted)-$0.96+49.5%

Cash & equivalents$62.1M+24.5%

Total debt$419.0K+204%

Total equity$324.0M+60.0%

Total assets$349.3M+62.1%

Operating cash flow-$41.9M+38.4%

Market cap$1.49B+62.1%

Return on equity-55.2%+8.0pp

Debt / equity0×0.0×

Current ratio14×-0.4×

Reported directly by ArriVent BioPharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.

The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is ArriVent BioPharma, Inc.'s proceeds from disposition of marketable securities and other investments?: ArriVent BioPharma, Inc. (AVBP) reported proceeds from disposition of marketable securities and other investments of $67.97M in Q1 2026.
How has ArriVent BioPharma, Inc.'s proceeds from disposition of marketable securities and other investments changed year-over-year?: ArriVent BioPharma, Inc.'s proceeds from disposition of marketable securities and other investments increased by 45.7% year-over-year, from $46.64M to $67.97M.